SAR245408

DRUG4 trials

Sponsors

Sanofi

Conditions

Neoplasm MalignantSolid Tumor Cancers

Phase 1

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

CompletedNCT01392924

SanofiNeoplasm Malignant

Start: 2011-08-31End: 2014-11-30Updated: 2014-12-03

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

CompletedNCT01436565

SanofiSolid Tumor Cancers

Start: 2011-11-30End: 2014-05-31Updated: 2014-06-13

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

CompletedNCT01587040

SanofiNeoplasm Malignant

Start: 2012-07-20End: 2018-05-23Updated: 2022-04-19

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

CompletedNCT01943838

SanofiNeoplasm Malignant

Start: 2013-10-31End: 2015-02-28Updated: 2016-04-22

Related Papers

Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma.

Journal of Clinical Oncology2015-05-201 citations